Supplementary Table 1.
Analysis of correlation between MLH1 expression, clinico-pathological features and markers in 245 invasive breast carcinomas
| N | MLH1 negative (n=4) | MLH1 positive (n=174) | p value | |
|---|---|---|---|---|
| Tumour size | 176 | 0.550* | ||
| T1 | 3 | 83 | ||
| T2 | 1 | 77 | ||
| T3 | 0 | 12 | ||
| Histological grade | 174 | 0.589* | ||
| I | 0 | 19 | ||
| II | 2 | 50 | ||
| III | 2 | 101 | ||
| Lympho-vascular invasion | 176 | 0.587** | ||
| present | 2 | 52 | ||
| absent | 2 | 120 | ||
| Lymph node metastasis | 172 | 0.307** | ||
| present | 4 | 113 | ||
| absent | 0 | 55 | ||
| ER | 178 | 0.499** | ||
| positive | 3 | 147 | ||
| negative | 1 | 27 | ||
| PR | 178 | 0.304** | ||
| positive | 2 | 127 | ||
| negative | 2 | 47 | ||
| HER2 | 178 | 0.095** | ||
| positive | 2 | 23 | ||
| negative | 2 | 151 | ||
| Ki67 | 166 | 0.674* | ||
| low (<10%) | 1 | 73 | ||
| intermediate | 2 | 67 | ||
| high (>30%) | 1 | 22 | ||
| Topoisomerase IIα | 163 | 0.625** | ||
| positive | 3 | 85 | ||
| negative | 1 | 74 | ||
| Cyclin D1 | 169 | 0.623* | ||
| low (Allred score 0-3) | 1 | 18 | ||
| intermediate (Allred score 4-5) | 1 | 33 | ||
| high (Allred score 6-8) | 2 | 114 | ||
| Bcl2 | 145 | 0.545** | ||
| positive | 1 | 97 | ||
| negative | 1 | 46 | ||
| FOXA1 | 146 | 1** | ||
| positive | 3 | 108 | ||
| negative | 0 | 35 | ||
| p53 | 166 | 1** | ||
| positive | 1 | 47 | ||
| negative | 2 | 116 | ||
| Cytokeratin 5/6 | 170 | 0.311** | ||
| positive | 1 | 14 | ||
| negative | 3 | 152 | ||
| Cytokeratin 14 | 176 | 1** | ||
| positive | 0 | 13 | ||
| negative | 4 | 159 | ||
| Cytokeratin 17 | 175 | 1** | ||
| positive | 0 | 19 | ||
| negative | 4 | 152 | ||
| Basal cytokeratins | 176 | 0.432** | ||
| positive | 1 | 22 | ||
| negative | 3 | 150 | ||
| EGFR | 178 | 0.281** | ||
| positive | 1 | 13 | ||
| negative | 3 | 161 | ||
| Caveolin 1 | 178 | 1** | ||
| positive | 0 | 14 | ||
| negative | 4 | 160 | ||
| Caveolin 2 | 165 | 1** | ||
| positive | 0 | 10 | ||
| negative | 4 | 151 | ||
| Nestin | 146 | 0.296** | ||
| positive | 1 | 15 | ||
| negative | 2 | 128 | ||
| Any basal marker | 176 | 0.476** | ||
| positive | 1 | 25 | ||
| negative | 3 | 147 | ||
| Molecular phenotype*** | 173 | 0.513* | ||
| luminal | 2 | 127 | ||
| HER2+ | 1 | 23 | ||
| basal-like | 1 | 29 | ||
| E-cadherin | 165 | 0.330* | ||
| normal | 2 | 101 | ||
| reduced | 1 | 10 | ||
| negative | 1 | 50 | ||
| HER2 CISH | 168 | 0.433** | ||
| amplified | 1 | 21 | ||
| not amplified | 3 | 143 | ||
| TOP2A CISH | 169 | 0.295** | ||
| amplified | 1 | 13 | ||
| not amplified | 3 | 152 | ||
| CCND1 CISH | 176 | 1** | ||
| amplified | 0 | 24 | ||
| not amplified | 4 | 148 |
*
Chi-squared test
**
Fisher's exact test
***
according to criteria by Nielsen et al [53].
CCND1: cyclin D1 gene; CISH: chromogenic in situ hybridisation; MLH1: mutL homolog 1; TOP2A: topoisomerase IIα gene.